A high throughput test for detecting neutralizing antibodies to SARS-CoV-2 скачать в хорошем качестве

A high throughput test for detecting neutralizing antibodies to SARS-CoV-2

The need for a reliable supply of accurate serology tests is paramount as countries globally have started opening their economies since the onset of the COVID-19 pandemic. Most ELISA-based serological tests for SARS-CoV-2 utilize either protein (typically receptor binding domain (RBD) or truncations of the spike protein and/or nucleocapsid) or antibody (anti-IgG or anti-IgM) coated plates for capture and detection of IgG and/or IgM. Even more important than just detecting antibodies is the ability to detect the antibodies blocking the virus entry into the cell. The newly developed cPass™ Neutralization Antibody Detection kit utilizes the interaction between RBD and the human ACE2 receptor to provide greatly improved speed, scalability and ease of use compared to the gold standard virus neutralization assay. Since it uses soluble RBD for detection, the assay is also isotype and species independent for highly specific and sensitive immunoglobulin detection across animal models and human samples.